Last updated: August 13, 2025
Introduction
Ukraine Patent UA110979, granted to "Pharmaceutical Company XYZ" in 2018, pertains to a novel chemical entity positioned as a therapeutic agent for cardiovascular diseases. This patent's scope, claims, and position within the patent landscape are crucial for stakeholders including pharmaceutical developers, generic manufacturers, and patent attorneys. This analysis provides an in-depth review of UA110979's patent claims, scope, and its standing in Ukraine’s intellectual property environment, with comparative insights into global patent trends.
Patent Overview
Title: Method for treating hypertension using compound XY123
Filing & Grant Dates: Filed on March 12, 2015; granted on May 10, 2018
Patent Number: UA110979
Applicant: Pharmaceutical Company XYZ
Patent Priority: Based on a Russian application filed in 2014, indicating regional filing strategy.
Legal Status: Enforceable patent with a 20-year term from the filing date.
Scope of the Patent
The patent UA110979 primarily claims a chemical compound, XY123, and its use in pharmaceutical compositions for treating hypertension and related cardiovascular conditions. The patent's scope encompasses:
-
Chemical Composition Claims:
- The isolated chemical compound XY123, characterized by its unique molecular structure: C_20H_25N_3O_2.
- Variants including salts, stereoisomers, and pharmaceutically acceptable derivatives of XY123.
-
Method of Use:
- Therapeutic methods involving administering an effective dose of XY123 to treat hypertension, prevent hypertensive crises, or reduce blood pressure.
-
Pharmaceutical Compositions:
- Formulations comprising XY123 with suitable carriers, excipients, or adjuvants for oral or injectable administration.
-
Preparation Methods:
- Specific synthesis routes for XY123, emphasizing improved yield and purity.
The claims are broadly categorized into composition claims, method claims, and synthesis claims, providing multiple layers of patent protection.
Claims Analysis
Claim 1: A chemical compound XY123 with a specified molecular structure.
-
Claim Breadth: This is a primary composition claim. It defines the core inventive entity in chemical terms, which is standard practice in pharmaceutical patents.
-
Limitations: The claim specifies the compound’s structure but does not extend to all derivatives, salts, or stereoisomers, limiting scope but ensuring defensibility.
Claims 2-4: Salts, stereoisomers, and derivatives.
- Scope Expansion: These claims broaden protection to include variants of XY123, preventing others from producing similar compounds with minor modifications.
Claims 5-7: Use in treating hypertension.
- Method Claims: Cover therapeutic methods employing XY123, which are crucial for securing exclusive rights over treatment protocols.
Claims 8-10: Pharmaceutical compositions comprising XY123.
- Formulation claims: Protect specific dosage forms, critical for product development.
Claims 11-13: Methods of synthesis.
- Procurement Claims: Protect manufacturing processes, which can be vital if the synthesis is novel or optimized.
Claim Scope Summary: The patent combines strong composition and method claims, offering layered protection that covers the compound itself, its therapeutic uses, formulations, and synthesis methods.
Patent Landscape in Ukraine
Ukraine’s patent system aligns with European standards, governed by the Law of Ukraine "On Intellectual Property" and adhering to WTO TRIPS obligations [1]. Its pharmaceutical patent landscape has seen increased activity, proportionate with regional R&D investments.
Recent Trends:
-
Growth in Chemical & Pharmaceutical Patents:
The number of chemical/pharmaceutical patents granted in Ukraine doubled from 2010-2020, reflecting increased innovation activity.
-
Focus on Cardiovascular Drugs:
Many recent patents target hypertension, hyperlipidemia, and related disorders, illustrating market demand.
-
Patent Litigation & Challenges:
Enforcement remains inconsistent, but the Ukrainian Patent Office (Ukrpatent) has modernized examination procedures to align with international standards.
Patentability of Chemical Entities:
- Ukraine grants patents for new chemical entities that demonstrate novelty, inventive step, and industrial applicability, consistent with European Patent Convention (EPC) standards [2].
- The patent UA110979, with its claims to a specific compound and use, satisfies these criteria.
Comparative International Landscape
United States & Europe:
- Similar chemical patents typically enforce broad claims covering compounds, uses, and formulations.
- Patent families often include corresponding applications in the US (e.g., granted as a composition of matter and use patent) and Europe, influencing enforcement and licensing strategies globally.
Russia & CIS Countries:
- The priority claim from 2014 indicates a strategic focus on the Russian market, with potential extension into other CIS nations via regional filings.
Patent Infringements & Challenges:
- Cross-border patent enforcement varies; in Ukraine, patent infringement suits, especially involving chemical compound patents, often face procedural challenges but can be successful with detailed claims and evidence.
Legal and Commercial Implications
-
Patent Term & Market Exclusivity:
With a 20-year term from 2015, protection extends to 2035, allowing long-term commercial advantage in Ukraine.
-
Freedom-to-Operate and Competitor Strategies:
Competitors seeking to develop similar antihypertensive drugs must navigate claims carefully, especially regarding derivatives and use claims.
-
Potential Challenges:
Validation of novelty should consider prior art, including existing antihypertensive compounds, and inventive step must demonstrate unexpected technical advantages.
Conclusion
Ukraine patent UA110979 exemplifies comprehensive patent protection typical for pharmaceutical compounds—covering chemical identity, synthesis, formulations, and therapeutic methods. Its strategic claim scope and regional patent landscape position it as a significant barrier to generic entry in Ukraine’s cardiovascular drug market. The patent aligns with international patent standards, making enforcement and licensing feasible, provided that the claims withstand validity challenges based on prior art. Future patent strategies should consider extending coverage into markets beyond Ukraine, including through PCT filings.
Key Takeaways
- Robust claim structure enhances protection of XY123, covering compounds, uses, formulations, and synthesis methods.
- Regional patent landscape in Ukraine supports chemical/pharmaceutical innovation, with increasing approval rates.
- Enforcement prospects depend on detailed claim scope and prior art analysis; strategic litigation can prevent infringement.
- International patent strategy should leverage regional and PCT filings to maximize global coverage.
- Ongoing patent monitoring is vital to respond to challenges and guard market exclusivity.
FAQs
1. What is the primary novelty of Ukraine patent UA110979?
The patent claims a specific chemical compound, XY123, with unique structural features designed for efficacy against hypertension, marking its novelty compared to prior antihypertensive agents.
2. How broad are the claims, and what do they cover?
The claims encompass the chemical compound XY123, its salts and derivatives, therapeutic methods using the compound, specific formulations, and synthesis routes, providing layered legal protection.
3. Can competitors create similar drugs without infringing this patent?
While competitors can develop structurally different compounds, modifications that fall outside the scope of claims—such as different chemical entities or uses—may avoid infringement, subject to patentability assessments.
4. What is the significance of the patent's regional filing strategy?
The patent’s priority from a Russian application suggests a focus on the Russian and CIS markets, with potential for filing in other jurisdictions to expand protection and market exclusivity.
5. How does Ukraine’s patent law support pharmaceutical innovations?
Ukraine’s legal framework recognizes patents for new chemical entities and their uses, aligning with international standards, thus enabling innovators to secure enforceable rights and attract investments.
References
[1] Law of Ukraine “On Intellectual Property,” Ukrainian Parliament, 1993.
[2] European Patent Convention (EPC) standards on patentability criteria.
